Olmetab
Generic Name
Olmesartan Medoxomil
Manufacturer
Incepta Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab 20 mg tablet | ৳ 4.50 | ৳ 45.00 |
Description
Overview of the medicine
Olmetab 20 mg tablet contains Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps to relax blood vessels, allowing blood to flow more easily.
Uses & Indications
Dosage
Adults
The usual recommended starting dose is 20 mg once daily. The dose may be increased to 40 mg once daily if blood pressure is not adequately controlled after 2 weeks. Maximum dose is 40 mg once daily.
Elderly
No initial dosage adjustment is generally required for elderly patients (≥65 years). However, caution should be exercised, and blood pressure should be closely monitored.
Renal_impairment
No dosage adjustment is needed for patients with mild to moderate renal impairment. For patients with severe renal impairment (creatinine clearance <20 mL/min), a lower starting dose (e.g., 10 mg) and careful monitoring are recommended. Not recommended in end-stage renal disease.
How to Take
Olmetab 20 mg tablet should be taken orally, once daily, with or without food. It is recommended to take the tablet at about the same time each day.
Mechanism of Action
Olmesartan Medoxomil is a prodrug that is rapidly converted to its active form, olmesartan, during absorption from the gastrointestinal tract. Olmesartan selectively blocks the binding of angiotensin II to the AT1 receptor in various tissues, including vascular smooth muscle and the adrenal gland. This blockade inhibits the vasoconstrictive and aldosterone-secreting effects of angiotensin II, leading to peripheral vasodilation and reduction in blood pressure.
Pharmacokinetics
Onset
Antihypertensive effect observed within 1 week, maximal reduction typically after 2-4 weeks.
Excretion
Approximately 35-50% excreted renally and the remaining is excreted via bile/feces.
Half life
Elimination half-life is approximately 13 hours.
Absorption
Rapidly and completely absorbed from the GI tract as olmesartan medoxomil and rapidly converted to active olmesartan. Absolute bioavailability is approximately 26%. Peak plasma concentration (Cmax) is reached in about 1-2 hours.
Metabolism
Olmesartan medoxomil is a prodrug and is hydrolyzed to olmesartan in the gastrointestinal tract. Olmesartan itself is not further metabolized and is not a substrate or inhibitor of cytochrome P450 enzymes.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan Medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
- Severe hepatic impairment.
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity. Monitor serum lithium levels.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and may worsen renal function in dehydrated patients or those with impaired renal function.
Potassium-sparing diuretics/Potassium supplements
May increase serum potassium levels, leading to hyperkalemia.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia or bradycardia. Treatment is symptomatic and supportive. If ingestion is recent, induce emesis or perform gastric lavage. Administer activated charcoal. Closely monitor vital signs and correct electrolyte imbalances.
Pregnancy & Lactation
Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity. Discontinue as soon as pregnancy is detected. Lactation: Not recommended during breastfeeding due to potential risk to the nursing infant.
Side Effects
Contraindications
- Hypersensitivity to Olmesartan Medoxomil or any component of the formulation.
- Pregnancy (second and third trimesters).
- Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m²).
- Severe hepatic impairment.
Drug Interactions
Lithium
Concurrent use may increase serum lithium concentrations and lead to lithium toxicity. Monitor serum lithium levels.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or renal impairment due to increased risk of hyperkalemia, hypotension, and renal impairment.
NSAIDs (Nonsteroidal Anti-inflammatory Drugs)
May reduce the antihypertensive effect of olmesartan and may worsen renal function in dehydrated patients or those with impaired renal function.
Potassium-sparing diuretics/Potassium supplements
May increase serum potassium levels, leading to hyperkalemia.
Storage
Store in a cool and dry place, below 30°C. Protect from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure) and possibly tachycardia or bradycardia. Treatment is symptomatic and supportive. If ingestion is recent, induce emesis or perform gastric lavage. Administer activated charcoal. Closely monitor vital signs and correct electrolyte imbalances.
Pregnancy & Lactation
Pregnancy: Contraindicated in the second and third trimesters due to fetal toxicity. Discontinue as soon as pregnancy is detected. Lactation: Not recommended during breastfeeding due to potential risk to the nursing infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from the date of manufacture. Refer to the packaging for the exact expiry date.
Availability
Available in pharmacies and hospitals
Approval Status
Approved by DGDA/FDA
Patent Status
Patent expired, generic available
Clinical Trials
Extensive clinical trials have demonstrated Olmesartan's efficacy in lowering blood pressure and reducing the risk of cardiovascular events in hypertensive patients. Key trials include those evaluating its use in monotherapy and combination therapy.
Lab Monitoring
- Serum creatinine and potassium levels should be monitored periodically, especially in patients with renal impairment or those receiving concomitant potassium-sparing diuretics.
- Liver function tests if clinically indicated.
Doctor Notes
- Educate patients on the importance of adherence to therapy and lifestyle modifications.
- Monitor serum potassium and renal function, especially in high-risk patients.
- Avoid concomitant use with aliskiren in diabetic or renally impaired patients.
Patient Guidelines
- Take the medicine exactly as prescribed by your doctor.
- Do not stop taking the medicine without consulting your doctor, even if you feel well.
- Report any unusual side effects, especially swelling of the face, lips, or tongue, to your doctor immediately.
- Inform your doctor about all other medications, including over-the-counter drugs and herbal supplements, you are taking.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Olmetab may cause dizziness or lightheadedness, especially at the start of treatment or when the dose is increased. Patients should be cautious when driving or operating machinery until they know how the medicine affects them.
Lifestyle Advice
- Maintain a healthy diet low in sodium and rich in fruits and vegetables.
- Engage in regular physical activity as advised by your doctor.
- Avoid smoking and limit alcohol consumption.
- Monitor your blood pressure regularly at home.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Olmetab Brand
Other medicines available under the same brand name
